U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with H

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
138015 Q2 2022 HYDROXYPROPYL CELLULOSE ORAL TABLET, FILM COATED 30mg Correction
138016 Q3 2022 HYDROXYPROPYL CELLULOSE ORAL TABLET, FILM COATED 25mg Correction
138104 Q3 2022 HYPROMELLOSE ORAL TABLET, MULTILAYER, EXTENDED RELEASE 8.40 mg Deletion
138105 Q3 2022 HYPROMELLOSE 2906 (4000 MPA.S) BUCCAL GUM, CHEWING 14.00 mg Deletion
138106 Q3 2022 HYPROMELLOSE 2910 (15 MPA.S) ORAL TABLET, COATED PARTICLES 42.50 mg 340mg Deletion
138107 Q3 2022 HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S) ORAL TABLET 19.83 mg Deletion
138108 Q3 2022 HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) ORAL TABLET, COATED PARTICLES 186.9 mg 1495mg Deletion
138277 Q2 2022 HYDROGENATED STARCH HYDROLYSATE SUBLINGUAL FILM 6.02 mg MDE Replacement
138278 Q3 2022 HYDROGENATED STARCH HYDROLYSATE SUBLINGUAL FILM 18mg MDE Replacement
138279 Q2 2022 HYDROXYPROPYL CELLULOSE (1600000 WAMW) BUCCAL FILM 43.60 mg MDE Replacement
138280 Q3 2022 HYDROXYPROPYL CELLULOSE (1600000 WAMW) BUCCAL FILM 87mg MDE Replacement
138281 Q2 2022 HYPROMELLOSE 2910 (15 MPA.S) VAGINAL INSERT 36.76 mg MDE Replacement
138282 Q3 2022 HYPROMELLOSE 2910 (15 MPA.S) VAGINAL INSERT 37mg MDE Replacement
138283 Q2 2022 HYPROMELLOSE 2910 (4000 MPA.S) OPHTHALMIC SOLUTION 0.5 %w/v MDE Replacement
138284 Q3 2022 HYPROMELLOSE 2910 (4000 MPA.S) OPHTHALMIC SOLUTION 2mg MDE Replacement
138285 Q2 2022 HYPROMELLOSE 2910 (6 MPA.S) ORAL GRANULE 1.00 mg MDE Replacement
138286 Q3 2022 HYPROMELLOSE 2910 (6 MPA.S) ORAL GRANULE 18mg MDE Replacement
138287 Q2 2022 HYPROMELLOSE 2910 (6 MPA.S) ORAL POWDER, FOR SUSPENSION 35.00 mg/ 5.00 ml MDE Replacement
138288 Q3 2022 HYPROMELLOSE 2910 (6 MPA.S) ORAL POWDER, FOR SUSPENSION 504mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: July 1, 2022
Database Last Updated: July 18, 2022

Back to Top